The efficacy of this combined therapy was based on the ICB (anti-PD-1) ability to reverse immune resistance through the reinvigoration of pre-existing exhausted tumor antigen-specific T cell responses, thus establishing a systemic immune memory that is capable of clearing tumors when re-challenged [255]. Here, PDCD1 is linked to neoplasm.